134 related articles for article (PubMed ID: 34762175)
41. A pilot study of multimodality therapy for initially unresectable liver metastases from colorectal carcinoma: hepatic resection after hepatic arterial infusion chemotherapy and portal embolization.
Akasu T; Moriya Y; Takayama T
Jpn J Clin Oncol; 1997 Oct; 27(5):331-5. PubMed ID: 9390211
[TBL] [Abstract][Full Text] [Related]
42. Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases.
Wang Y; Yuan YF; Lin HC; Li BK; Wang FH; Wang ZQ; Ding PR; Chen G; Wu XJ; Lu ZH; Pan ZZ; Wan DS; Sun P; Yan SM; Xu RH; Li YH
Chin J Cancer; 2017 Oct; 36(1):78. PubMed ID: 28969708
[TBL] [Abstract][Full Text] [Related]
43. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases.
Jaeck D; Oussoultzoglou E; Rosso E; Greget M; Weber JC; Bachellier P
Ann Surg; 2004 Dec; 240(6):1037-49; discussion 1049-51. PubMed ID: 15570209
[TBL] [Abstract][Full Text] [Related]
44. Impact of hepatic lymph node metastasis on survival of patients with synchronous resectable or unresectable liver metastases of colorectal cancer.
Ishibashi K; Ishida H; Ohsawa T; Okada N; Kumamoto K; Haga N
Tech Coloproctol; 2013 Feb; 17(1):51-7. PubMed ID: 22936589
[TBL] [Abstract][Full Text] [Related]
45. Impact of Surgical Management for Relapse After Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastasis: A Retrospective Cohort Study.
Chen Y; Zhu D; Chen M; Xu Y; Ye Q; Wang X; Xu P; Feng Q; Ji M; Wei Y; Fan J; Xu J
Clin Colorectal Cancer; 2023 Dec; 22(4):464-473.e5. PubMed ID: 37730473
[TBL] [Abstract][Full Text] [Related]
46. Clinical Impact of FOLFOXIRI Aiming for Conversion Surgery in Unresectable Multiple Colorectal Liver Metastasis.
Morine Y; Ikemoto T; Iwahashi S; Saito YU; Yamada S; Takasu C; Higashijima J; Imura S; Shimada M
Anticancer Res; 2019 Sep; 39(9):5089-5096. PubMed ID: 31519620
[TBL] [Abstract][Full Text] [Related]
47. Clinical features and prognosis in hepatectomy for colorectal cancer with centrally located liver metastasis.
Kuo IM; Huang SF; Chiang JM; Yeh CY; Chan KM; Chen JS; Yu MC
World J Surg Oncol; 2015 Mar; 13():92. PubMed ID: 25889950
[TBL] [Abstract][Full Text] [Related]
48. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
Ye LC; Liu TS; Ren L; Wei Y; Zhu DX; Zai SY; Ye QH; Yu Y; Xu B; Qin XY; Xu J
J Clin Oncol; 2013 Jun; 31(16):1931-8. PubMed ID: 23569301
[TBL] [Abstract][Full Text] [Related]
49. Reconsideration of the indications for adjuvant chemotherapy for liver metastases from colorectal cancer after initial hepatectomy.
Hirokawa F; Hayashi M; Miyamoto Y; Asakuma M; Shimizu T; Komeda K; Inoue Y; Uchiyama K
Ann Surg Oncol; 2014 Jan; 21(1):139-46. PubMed ID: 24121880
[TBL] [Abstract][Full Text] [Related]
50. [Diagnosis and treatment of colorectal liver metastases - workflow].
Grundmann RT; Hermanek P; Merkel S; Germer CT; Grundmann RT; Hauss J; Henne-Bruns D; Herfarth K; Hermanek P; Hopt UT; Junginger T; Klar E; Klempnauer J; Knapp WH; Kraus M; Lang H; Link KH; Löhe F; Merkel S; Oldhafer KJ; Raab HR; Rau HG; Reinacher-Schick A; Ricke J; Roder J; Schäfer AO; Schlitt HJ; Schön MR; Stippel D; Tannapfel A; Tatsch K; Vogl TJ;
Zentralbl Chir; 2008 Jun; 133(3):267-84. PubMed ID: 18563694
[TBL] [Abstract][Full Text] [Related]
51. Clinical relevance of oncologic prognostic factors in the decision-making of pre-hepatectomy chemotherapy for colorectal cancer hepatic metastasis: the priority of hepatectomy.
Chan KM; Wu TH; Wang YC; Lee CF; Wu TJ; Chou HS; Lee WC; Chiang JM; Chen JS
World J Surg Oncol; 2018 Feb; 16(1):24. PubMed ID: 29415722
[TBL] [Abstract][Full Text] [Related]
52. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Gruenberger T; Bridgewater J; Chau I; García Alfonso P; Rivoire M; Mudan S; Lasserre S; Hermann F; Waterkamp D; Adam R
Ann Oncol; 2015 Apr; 26(4):702-708. PubMed ID: 25538173
[TBL] [Abstract][Full Text] [Related]
53. Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review.
Bolhuis K; Kos M; van Oijen MGH; Swijnenburg RJ; Punt CJA
Eur J Cancer; 2020 Dec; 141():225-238. PubMed ID: 33189037
[TBL] [Abstract][Full Text] [Related]
54. Debate: Improvements in Systemic Therapies for Liver Metastases Will Increase the Role of Locoregional Treatments.
Kawaguchi Y; De Bellis M; Panettieri E; Duwe G; Vauthey JN
Surg Oncol Clin N Am; 2021 Jan; 30(1):205-218. PubMed ID: 33220806
[TBL] [Abstract][Full Text] [Related]
55. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
Lévi FA; Boige V; Hebbar M; Smith D; Lepère C; Focan C; Karaboué A; Guimbaud R; Carvalho C; Tumolo S; Innominato P; Ajavon Y; Truant S; Castaing D; De Baere T; Kunstlinger F; Bouchahda M; Afshar M; Rougier P; Adam R; Ducreux M;
Ann Oncol; 2016 Feb; 27(2):267-74. PubMed ID: 26578731
[TBL] [Abstract][Full Text] [Related]
56. Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial.
Hu H; Wang K; Huang M; Kang L; Wang W; Wang H; Qiu M; Lin R; Zhang H; Lan P; Wu X; Liu G; Wan Y; Liu M; Zhou Z; Huang Y; Li F; Zhang J; Cai Y; Ma T; Zhou J; Wang H; Ling J; Cai Y; Wu Z; Luo S; Ling L; Deng Y
Oncologist; 2021 Jan; 26(1):e90-e98. PubMed ID: 33400355
[TBL] [Abstract][Full Text] [Related]
57. Risk factors for early extrahepatic metastasis in patients with liver metastasis from colorectal carcinoma.
Sasaki A; Iwashita Y; Shibata K; Matsumoto T; Ohta M; Inomata M; Kitano S
Hepatogastroenterology; 2005; 52(66):1840-4. PubMed ID: 16334789
[TBL] [Abstract][Full Text] [Related]
58. An update on chemotherapy of colorectal liver metastases.
Wang CC; Li J
World J Gastroenterol; 2012 Jan; 18(1):25-33. PubMed ID: 22228967
[TBL] [Abstract][Full Text] [Related]
59. Unresectable colorectal liver metastases: the safety and efficacy of conversion therapy using hepatic arterial infusion immunochemotherapy with 5-fluorouracil and polyethylene glycol-interferon α-2a.
Nakai T; Okuno K; Kitaguchi H; Ishikawa H; Yamasaki M
World J Surg; 2013 Aug; 37(8):1919-26. PubMed ID: 23564218
[TBL] [Abstract][Full Text] [Related]
60. Up-front systemic chemotherapy is a feasible option compared to primary tumor resection followed by chemotherapy for colorectal cancer with unresectable synchronous metastases.
Niitsu H; Hinoi T; Shimomura M; Egi H; Hattori M; Ishizaki Y; Adachi T; Saito Y; Miguchi M; Sawada H; Kochi M; Mukai S; Ohdan H
World J Surg Oncol; 2015 Apr; 13():162. PubMed ID: 25908502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
